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Novelty and Impact 
Using pre-diagnostic blood samples of pancreas cancer cases and controls from the EPIC 
cohort, we examined the prospective detection capacity for pancreas cancer by apolipoprotein 
A2 isoforms in combination with CA19-9. Compared to CA19-9 alone, the combined markers 
showed significantly improved detection discrimination up to 18 months before usual diagnosis. 
The combined markers could be used in multi-modal screening strategies, to enrich a general-
population screening sample with pancreas cancer cases before further examination by 
imaging. 
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ABSTRACT 
Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with 
pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform 
(―ApoA2-ATQ/AT‖), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an 
early detection biomarker for pancreatic cancer. 
We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with 
pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma 
samples collected up to 60 months prior to diagnosis. The detection discrimination statistics 
were calculated for risk scores by strata of lag-time. 
For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer 
patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, 
and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. 
Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within 
>6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 
0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities 
were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 
29% and 36% for CA19-9 alone.  
Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve 
detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may 
provide a useful first measure for pancreatic cancer detection prior to imaging. 
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Words count:  Introduction – Discussion = 3,584
INTRODUCTION 
Early detection of pancreatic ductal adenocarcinomas (PDAC) is difficult because the pancreas 
is located deep within the abdominal cavity, and because patients do not present unique 
symptoms 1. Given the low incidence of pancreatic cancer, general population screening is not 
cost-effective with current technology, which requires relatively expensive (magnetic resonance 
imaging) or invasive (e.g., endoscopic ultrasonography [EUS]) imaging modalities 2, 3. However, 
a feasible screening strategy could consist of a pre-screen based on noninvasive biomarkers, 
followed by imaging only among individuals who have a positive biomarker test. 
Carbohydrate antigen 19-9 (CA19-9) is the conventional biomarker for the detection of PDAC, 
and is commonly used for monitoring therapy response in PDAC patients 4, 5. Limitations of 
CA19-9, however, are that it can be increased in several benign diseases and multiple types of 
advanced gastrointestinal adenocarcinoma 6, and that it may have only limited sensitivity for 
small tumors in still curable stage 7. Furthermore, CA19-9 is not expressed at all in individuals 
genetically expressing non-sialylated Lewis blood group antigens 8, 9. 
Recently, we identified unique processing patterns of c-terminal amino acids of apolipoprotein 
A2 (ApoA2) in patients with pancreatic cancer 10-12. In the bloodstream ApoA2 can be found in 5 
dimeric isoforms (ApoA2i) 10-13. In healthy subjects, 3 basic isoforms are found which we labeled 
ApoA2-ATQ/ATQ, ApoA2-ATQ/AT and ApoA2-AT/AT), by the lengths of each of the homomers. 
Patients with PDAC show additional isomers formed through two aberrant processing patterns 
of ApoA2i: a hyper-processing pattern of ApoA2i, which leads to predominantly light isoforms 
such as ApoA2-AT/AT, ApoA2-AT/A and ApoA2-A/A, and a hypo-processing pattern which 
leads to a predominance of heavy isoforms such as ApoA2-ATQ/ATQ 11, 12. The aberrant 
processing is likely a consequence of abnormal expression and release of carboxypeptidase A, 
a digestive enzyme that is primarily synthesized by the pancreas, and leads to a reduction in 
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plasma levels of ApoA2-ATQ/AT, the major intermediate isoform of ApoA2i, in comparison with 
healthy subjects. Aberrant processing of ApoA2 is observed not only in relation to pancreatic 
malignancies (including early-stage cancers), but also in individuals with intraductal papillary 
mucinous neoplasia (IPMN) and other pancreatic conditions (e.g. chronic pancreatitis) 
predisposing to pancreatic cancer development 10-12. 
In 2015, we developed an enzyme-linked immunosorbent assay (ELISA) method to determine 
blood concentrations of the intermediate ApoA2-ATQ/AT isoform. In validation studies jointly 
conducted in Japan and within the US National Cancer Center Early Detection Research 
Network (NCI EDRN), we then demonstrated the utility of this novel assay for pancreatic cancer 
detection, and showed that a combination of the ApoA2i assay with CA19-9 significantly 
improved diagnostic accuracy compared to CA19-9 alone 11. These studies, however, were 
based on case-control comparisons of patients already diagnosed with PDAC and cancer-free 
control subjects, and thus did not allow any evaluation of the lead time by which the markers 
may help anticipate cancer diagnosis. 
Here, we present the results of a study using prospectively collected samples from the 
European Prospective Investigation into Cancer (EPIC) cohort. We measured ApoA2i and 
CA19-9 in 156 patients with PDAC diagnosed within 5 years after blood donation and 217 
matched control subjects. The objectives of our study were to evaluate: (i) the early detection 
performance of the two markers in the short (within 0–6 months), middle (>6–18 months) and 
longer term (>18–60 months), and (ii) the improvement in detecting PDAC in patients using the 
combination assay with ApoA2i and CA19-9, as compared to CA19-9 alone. 
10 
MATERIALS AND METHODS 
Case control study nested within the European EPIC cohort 
We conducted a case-control study nested within the European EPIC cohort (―European 
Prospective Investigation into Cancer‖) – a population-based, multicenter prospective cohort 
study in 10 Western European countries 14, 15. A short description of data collection and 
prospective case ascertainment methods in the EPIC cohort is in the Supplemental Methods.  
The present study includes all incident cases of invasive, exocrine pancreatic cancer with ICD 
codes C25 (25.0–25.3, 25.7–25.9) who were clinically diagnosed within maximally 5 years after 
blood donation (N=156). Of these, 106 (68%) were microscopically confirmed, whereas the 
remaining diagnoses (33%) were based on a combination of clinical symptoms, physical 
examination and imaging. Exclusion criteria were the occurrence of other malignant tumors 
preceding the diagnosis of pancreatic cancer, except for non-melanoma skin cancer, and the 
non-availability of blood specimens. For each PDAC case, control participants were randomly 
selected among appropriate risk sets consisting of all cohort members with a blood sample, 
alive and free of cancer at the time of diagnosis of the index case. In view of cost-efficiency, one 
control was matched to cases with >2–5 years of follow-up, whereas two controls were matched 
to cases with 0–2 years of follow-up, where strongest discrimination was expected. An 
incidence density sampling protocol was used, such that in principle the controls could include 
study participants who became a case later in time and each control subject could be sampled 
more than once 16. The control participants actually drawn, however, did not include any of the 
future cases of pancreatic cancer detected so far in the EPIC cohort, and neither was any other 
form of cancer detected among the controls within their first three years of prospective follow-
up. Case and control subjects were matched on study recruitment center, sex, length of follow-
up, age at blood collection (±6 months), date of blood collection (±2 month), time of blood 
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collection (±2 hours) and use of oral contraceptives or postmenopausal hormone replacement 
therapy (OC/HRT). The final sample size was 156 cases and 213 matched controls. 
Laboratory assays 
The plasma samples of pancreatic cancer cases and control subjects samples were split into 
batches such that matched case–control sets and samples from the same study center were 
kept together in the same batches, and with blinding of case-control status.  
Measurements of CA19-9 were performed using an established ELISA kit (Lumipulse Presto 
CA19-9; Fujirebio, Inc., Tokyo, Japan). Laboratory values for CA19-9 of 37 samples (cases = 
15, controls = 22) were below the detection limit value of 2 U/mL, and this lower threshold value 
was thereafter assigned to all 37 samples. 
Measurements of ApoA2-ATQ/ATQ and ApoA2-AT/AT were performed by an ApoA2i 
measurement kit (Human ApoA2 C-terminal ApoA2 ELISA Kit; Toray Industries, Inc., Tokyo, 
Japan), which uses antibodies specific for each of the homodimers, according to the instruction 
manual. We then calculated the concentration of ApoA2-ATQ/AT hetero-dimers by the formula:                                                 , 
as described and in a previous report 11. Further details on ApoA2 isoform assays and 
calculation of ApoA2-ATQ/AT concentrations assay are in Supplemental Figure S1. 
Informed consent and data protection 
All participants had given their consent for future analyses of their blood samples and the 
present study was approved by the IARC Ethics Committee and the Institutional Review Board 
of the University of Heidelberg. 
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Statistical analyses 
CA19-9 marker levels were log2-transformed, to achieve approximate normality of their 
distribution; statistical analyses of ApoA2 isoforms were all performed on the untransformed 
scale. To examine how the early detection and/or risk prediction capacities of the biomarkers 
changed with time between blood draw and clinical cancer diagnosis, all analyses were 
performed within strata of lag-time (≤6 months, >6-18 months, >18-36 months and >36-60 
months). The difference of marker distributions among future pancreatic cancer cases and 
controls was tested with Wilcoxon’s signed rank test.  
The discrimination between future cancer cases and control subjects was described using ROC 
(receiver operating characteristic) analyses, with the area under the curve (AUC), also known as 
the C-(concordance) statistic, as an overall measure for discrimination capacity. Additionally, we 
estimated the diagnostic (early detection) sensitivities of each marker at cut-off points 
corresponding to 95% and 98% specificity, determined on crude values of the biomarkers and 
after adjustment for matching factors in our full dataset for all control subjects (N = 213).   
ROC curves were estimated either for crude marker measurements, without any adjustment, or 
for risk scores with CA19-9 or ApoA2-ATQ/AT markers as the major discrimination variables, 
using unconditional logistic regression models that included the matching factors as additional 
adjustments. Analyses directly based on marker measurements without further adjustments 
have the advantage that they allow use of pre-established marker cut-points, as used in other 
studies. As a complementary analysis, the adjusted model estimates account for the fact that 
the distribution of controls in our matched sample is not representative of the general 
population, and provide estimates of the general additional discriminative capacity of the 
markers over the risk factors included for matching17.  
Multivariate models were also used to examine the discrimination capacity of CA19-9 and 
ApoA2 markers in combination. To test for improvement in discrimination for combined vs. 
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single-marker models the statistical fit of nested models was compared with type-III F-tests 
within the logistic models. In addition, we calculated the continuous net reclassification 
improvement (NRI(>0)), which represents the net percent of case and control subjects correctly 
reclassified as a result of the added marker 18. Internal validation with 1000-fold bootstrapping 
was applied to adjust the results on discriminative capacity from multivariate models for over-
estimation.  
All analyses were conducted in SAS (version 9.4, SAS Institute). 
RESULTS 
Of the 156 case patients examined in this study, 106 (68%) were microscopically confirmed, 
whereas the remaining 32% were of unknown morphology (Table 1). At clinical diagnosis, 14 
patients (9%) had localized disease, 73 (47%) had metastatic disease and 69 (44%) were 
classified as having unknown disease spread. The median age at diagnosis was 60.9 years 
(range: 37.2–79.6). At the time of blood donation, case patients smoked significantly more often 
than controls. In addition, case patients had a marginally higher baseline BMI than controls. The 
prevalence of self-reported diabetes at time of recruitment was only marginally higher among 
future pancreatic cancer patients (9%) as compared to the controls (7%); for some of the cancer 
patients, these self-reports likely excluded undiagnosed diabetes that may have developed 
shortly before cancer diagnosis. 
Between CA19-9 and ApoA2-ATQ/AT no meaningful correlations were observed, either among 
the controls (r = -0.04, Supplemental Table S1 and Supplemental Figure S2) or among the 
cases (r = -0.10), even when only cases were considered whose blood samples had been taken 
shortly before diagnosis. None of the markers showed significant associations with BMI or self-
reported pre-existing diabetes; however, ApoA2-ATQ/AT was lower among current compared to 
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never smokers (P = 0.02), and increased among controls within the higher alcohol intake 
categories (>12g/d; P = 0.005 for current consumption at baseline) (Supplemental Table S1).  
Box and whisker plots (Figure 1) show that, for CA19-9, the marker distribution among the 
future case patients started to diverge from that of the controls about 18 months prior to clinical 
diagnosis (>6-18 months, Wilcoxon’s p-value = <0.001) and this difference grew larger as the 
lag time diminished to 6 months or less (p=<0.001). For ApoA2-ATQ/AT, the marker distribution 
for future cancer patients also started diverging from that of the controls about 18 months prior 
to diagnosis ((>6-18 months, p=0.01) tending towards lower levels for future cases as compared 
to the controls. 
In basic univariate ROC analyses directly based on marker measurements, both biomarkers 
showed a diminishing capacity to discriminate between future case patients and cancer-free 
individuals with increasing time lags between blood donation and tumor diagnosis (Figure 2). 
For CA19-9, the C-statistic equaled 0.80 for plasma samples taken ≤6 months before diagnosis, 
0.71 for lag times of >6-18 months, and less than 0.60 for lag times longer than 18 months.  At 
the 98% specificity cut-point (38.0 U/mL) the sensitivity (SE98) estimate was 0.50 for lag times 
less than 6 months, and 0.29 for lag times of >6-18 months (Table 2). Using the predefined cut-
point of 37 U/mL, frequently used in diagnostic settings 19, identical estimates for specificity 
(98%) and sensitivity (0.50) were obtained. For ApoA2-ATQ/AT, the C-statistics at lag times ≤6, 
>6-18 and >18 months were 0.62, 0.65 and 0.50, respectively, and using a 98% specificity cut-
point (27.7 µg/mL) sensitivity (SE98) estimates were 0.14, 0.21 and 0.19, respectively. At more 
lenient 95% specificity cut-points the detection sensitivities were all slightly higher for both 
CA19-9 and ApoA2-ATQ/AT (Table 2). Focusing on biomarker measurements less than 18 
months prior to cancer diagnosis, adding ApoA2-ATQ/AT to a logistic regression model with 
only CA19-9 significantly improved model fit (p=0.02), as well as the early detection 
discrimination (for the combined model, C=0.75 vs. C=0.74, with a continuous net 
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reclassification improvement (NRI) of 25%. Further differentiating the analyses by lag-times of 
≤6 months or >6-18 months showed that, especially for lag times of >6-18 months the joint 
marker discrimination was significantly better than for CA19-9 alone (C=0.75 vs. 0.71 P=0.022, 
NRI=35%). Combining CA19-9 and ApoA2-ATQ/AT using pre-defined cut-off values of 37 U/mL 
for CA19-9 19 or 27.7 µg/mL for ApoA2-ATQ/AT (based on the cut-point at 98% specificity within 
our data; Supplemental Figure S2), the sensitivity by which future cases were diagnosed 
within ≤18, >6-18 or >18-60 months was 45%, 39%, or 8%, respectively at an overall specificity 
of 96% (Table 3). With slightly modified cut points (38 U/mL for CA19-9, 25.0 µg/mL for ApoA2-
ATQ/AT), fixing the joint specificity at 98%, the two markers combined yielded sensitivities of 
43%, 36% and 7% respectively (Table 3), as compared to 36%, 29%, and 5% for CA19-9 alone 
(Table 2). Sensitivity analyses restricting to microscopically confirmed pancreas cancer (N=106) 
did not reveal any major discrepancies compared to analyses in the full dataset (all pancreas 
cancer outcomes; N=156) (supplementary Table S2).  
In multivariable models adjusting for the matching factors as co-variates, and using 
bootstrapping to correct for possible overfitting, ROC curves (C-statistics) and estimates of 
SE98 or SE95 were generally  comparable to univariate analyses based directly on the marker 
measurements (see Table 2 and Supplemental Figure S3). Similar to the unadjusted 
analyses, estimated C-statistics from the adjusted models show on increase in detection 
discrimination within time windows ≤18 months when the two biomarkers are combined, as 
compared to either biomarker alone (Supplementary Figure S3). Further model adjustments 
for smoking status (current, past, never), alcohol consumption, BMI or prevalent diabetes, or 
excluding individuals with a history of heavy alcohol drinking [>60g/d, 5% prevalence, N=26] or 
with self-reported baseline history of prevalent diabetes [N=30], did not substantially change any 
of the above discrimination estimates [results not reported in tables].  
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DISCUSSION 
In this prospective study the combination of CA19-9 with ApoA2-ATQ/AT showed a moderate 
but significant improvement in early detection discrimination for pancreatic cancer, compared to 
CA19-9 alone. In plasma samples predating cancer diagnosis up to 18 months, the two markers 
combined provided a detection sensitivity of 43% at 98% specificity vs. 36% for CA19-9 alone. 
This discrimination improvement was driven mostly by cases diagnosed within a >6-18 months 
lag time after blood donation (C-statistic of 0.74 for the markers combined [adjusted model: 
0.76] vs. 0.71 [adjusted: 0.73] for CA19-9 and 0.72 [adjusted: 0.71] for ApoA2-ATQ/AT 
respectively). For both markers, the discrimination capacity waned to insignificant levels at lag 
times between blood sampling and diagnosis greater than 18 months.  
For CA19-9, two further prospective studies have recently investigated early detection capacity 
in pre-diagnostic blood samples 20, 21. In the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS), using the standard cut-point of 37 U/ml O’Brien et al. observed sensitivities of 53%, 
59% and 18%, respectively, in blood samples drawn ≤6, >6-12 and >12-24 months prior to 
diagnosis, at specificities of 96-100% – findings very similar to ours – and the authors concluded 
that CA19-9 has encouraging sensitivity for detecting preclinical pancreatic cancer. By contrast, 
an investigation in the US PLCO cohort revealed lower sensitivity (38%) and specificity (93%) 
compared to O’Brien`s and our studies, and a C-statistic of only 0.695, for cases diagnosed 
within 1-12 months after blood draw.  
For ApoA2-ATQ/AT, our previous studies in Japan showed a strong capacity to distinguish 
patients with stage-I, -II, -III, or -IV of PDAC from healthy controls, with estimated C-statistics 
greater than 0.92 11. In this previous study, diagnostic discrimination by ApoA2-ATQ/AT 
measurements was as good as, or even stronger than, that by CA19-9 for both early and late-
stage PDAC (C-statistics all cases 0.94 vs. 0.90, stage-I 0.94 vs. 0.83, stage-II 0.96 vs. 0.95, 
stage-III 0.93 vs. 0.90, stage-IV 0.95 vs. 0.88, respectively). These initial findings were largely 
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confirmed in a further, blinded validation study of diagnostic accuracy for distinguishing PDAC of 
stage-I and -II from healthy controls, in collaboration with the NCI EDRN, which also showed 
higher C-statistics for ApoA2-ATQ/AT than for CA19-9 (0.81 vs. 0.78) 11. Finally, our previous 
study in the NCI EDRN showed that the combined assays for ApoA2-ATQ/AT and CA19-9 
improved diagnostic discrimination as compared to either marker alone (0.88, 0.81, and 0.78 for 
the combined assay, ApoA2-ATQ/AT and CA19-9, respectively).  
Pancreatic cancer screening efforts currently focus on high-risk groups with familial pancreatic 
cancer clustering due to heritable cancer syndromes. However, 90% of pancreatic cancers 
develop as sporadic tumors with much lower population incidence rates, prohibiting the direct 
use of expensive (MRI) or potentially invasive (e.g, EUS) imaging modalities as tools for 
generalized pancreatic cancer screening. Thus, current research focuses on strategies for 
multimodal screening, using blood-based markers to enrich the screening population with 
individuals at increased risk of having PDAC and to target diagnostic imaging towards a much 
smaller part of the population while still capturing a majority of pancreatic cancer cases. 
Data from screening studies among high-risk individuals indicate a sensitivity of about 56% at 
about 97% specificity for MRI-based detection of resectable, early-stage (N0-M0) PDAC 22, and 
in other prospective screening studies the general population prevalence of detectable 
pancreatic cancer has been estimated to be around 0.03 - 0.07% 23. Based on these data, it can 
be calculated 24 that complementary biomarkers should have a minimal sensitivity at least 15 
times their false-positive detection rate (e.g., a sensitivity of 30% at a specificity of 98%) to yield 
an overall positive predictive value (PPV) for multi-modal biomarker-plus-MRI screening greater 
than 0.10 – a PPV threshold at which screening will prompt no more than 9 invasive diagnostic 
procedures (e.g., EUS, biopsies) for one true positive case of pancreatic cancer diagnosed.  For 
blood samples taken >6-18 months before usual diagnosis – a time window that may include a 
high proportion of patients with tumors in still resectable stage 25 – our data indicate 36% 
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detection sensitivity at 98% specificity [0.43 for the period 0-18 months] for CA19-9 combined 
with ApoA2-ATQ/AT. 
Evaluation of early detection markers in clinical context, comparing between clinically diagnosed 
cases and controls, often has the limitation that either cases have already advanced disease or, 
if disease is still early-stage (which for pancreas cancer is very rare), these cases may not 
represent average early-stage patients in the general population. For example, it is possible that 
early-stage tumors spontaneously diagnosed after symptoms include a higher than average 
proportion of more slowly growing, comparatively less aggressive tumors. Often, markers that 
were initially found to distinguish clinical cancer cases (even in early stage) from cancer-free 
controls failed upon cross-validation in prospective cohort studies. 
The prospective design of our study ensures rigorous internal validity for the evaluation of 
marker differences between case and control participants, and allowed analyses by lagtime 
since blood donation, while adjusting for potential confounders. The combination of ApoA2-
ATQ/AT and CA19-9 showed 43% sensitivity at 98% specificity for cases diagnosed >6-18 
months after blood donation. This finding suggests diagnostic sensitivity of this marker 
combination for earlier stage disease, as detecting cancer sufficiently in advance of usual 
symptomatic diagnosis is generally believed to improve chances for successful surgical 
intervention and long-term survival. However, a limitation of our and other population-based 
cohort studies is that no information is available about the patients’ tumor stages at the time 
they provided their blood samples. Thus, although our data suggest that a meaningful 
proportion of cases could have been detected at least 6 months earlier, it remains speculative 
whether indeed those patients whose tumor might have been detectable earlier would have had 
a survival benefit if detected at that time point. Independent, prospective screening trials will be 
required to answer the question, whether screening by CA19-9 and ApoA2-ATQ/AT will lead to 
a significant shift in tumor stage at diagnosis and improved survival. A further limitation of our 
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study may be that we had no information on prevalent chronic pancreatitis or other non-
malignant conditions that could have affected CA19-9 or ApoA2-ATQ/AT measurements, 
although general population prevalence of such conditions is known to be low. During follow-up, 
all control subjects have so far remained free of pancreas cancer up to 15 years after blood 
donation, and none of the control subjects developed any other cancer within less than three 
years. Finally, in spite of the very large size of the European EPIC cohort, due to the relatively 
low incidence rate of pancreas cancer the numbers of cases detected within short lag times 
after blood donation remain modest, and more precise estimation of the diagnostic 
performances of CA19-9 and other detection markers eventually may require the combined 
resources of larger cohort consortia. External cross-validation of the combined CA19-9 plus 
ApoA2-ATQ/AT marker set will also be needed in view of possible over-estimation of their joint 
detection prediction, which may result when the prediction measure is computed in the same 
population where the value of the marker was assessed and its threshold decided, as in our 
single study.   
In conclusion, we found that compared to CA19-9 alone the combination of CA19-9 and ApoA2-
ATQ/AT can significantly improve discrimination for early detection of pancreatic cancer, as 
judged by the increase in sensitivity, at elevated specificity, for plasma measurements up to 18 
months before diagnosis under usual care. This improvement in sensitivity may allow a 
significant enrichment of a general-population screening sample before further examination by 
non-invasive (e.g. MRI) imaging. The absolute sensitivity at high (e.g. 98%) specificity remained 
modest, however, even for the combination of CA19-9 and ApoA2-ATQ/AT. The discovery and 
validation of other complementary markers 26 27 28 may further improve the sensitivity for 
identification of individuals with preclinical pancreatic cancer in multi-modal screening strategies. 
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Table 1. Baseline characteristics of cases and controls [median (min–max) or N (%)]
Cases (N = 156) Controls (N = 213) Pa 
Men / Women 85 (53%) / 74 (47%) 115 (53%) / 102 (47%) 
Age at blood draw, years 58.1 (34.9-75.7) 58.0 (34.5-75.4) 
BMI, kg/m² 26.7 (19.0-38.9) 26.0 (14.7-40.6) 
< 25 56 (36) 84 (39) 0.067 
≥ 25 100 (64) 129 (61) 
Smoking 
Never 61 (39) 93 (44) 0.024 
Former 47 (30) 77 (36) 
Current 47 (30) 40 (19) 
Unknown 1 3 (1) 
Alcohol consumption 
Yes 133 (85) 187 (88) 0.446 
Non drinker 22 (14) 25 (12) 
Unknown 1 1 
Diabetesb 
Yes 14 (9) 16 (7) 0.095 
No 125 (80) 177 (83) 
Unknown 17 (11) 20 (10) 
Case characteristics 
Age at diagnosis, median (range), years 60.9 (37.2-79.6) — 
Lag time, median (range), months 35 (1-60) — 
Morphology of the tumor 
 Adenocarcinoma 106 (68) — 
Tumor site 
Head 82 (53) — 
Body 12 (8) — 
Tail 8 (5) — 
Unspecific 54 (35) — 
Disease spread 
Localized 14 (9) — 
Metastatic 73 (47) — 
Unknown 69 (44) — 
Basis of tumor diagnosis 
Microscopically confirmed 106 (68) — 
Other (i.e. imaging, clinical symptoms) 50 (32) — 
Markerc
CA19-9 (U/mL) 12.1 (10.1-14.6) 6.8 (6.2-7.4) 0.101 
ApoA2-AT/AT (µg/mL) 43.2 (37.8-49.4) 48.7 (45.6-52.0) 0.480 
ApoA2-ATQ/ATQ (µg/mL) 41.4 (38.7-44.2) 42.9 (41.1-44.7) 0.892 
ApoA2-ATQ/AT (µg/mL) 42.2 (39.9-44.7) 45.7 (44.5-46.8) 0.193 
a P values determined using paired t-tests or generalized McNemar’s test. 
b Self-reported at baseline. 
c Presented as geometric mean (95% CI). 
Note: BMI = body-mass-index 
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Table 2. Sensitivity at 95% and 98% specificity of pancreatic cancer detection by time 
between blood draw and diagnosis, for crude marker measurements and with 
adjustments for case-control matching factorsa 
a adjustment factors were: study recruitment country, sex, age at blood collection, and exogenous 
hormone use (contraceptive OC/HRT) at time of blood donation 
Note: SE95 = sensitivity at 95% specificity; SE98 = sensitivity at 98% specificity; CI = confidence interval 
Lag-time 
(months) 
threshold 95 
crude 
SE95 (95% CI) 
crude 
SE95 (95% CI) 
adjusted 
threshold 98 
crude 
SE98 (95% CI) 
crude 
SE98 (95% CI) 
adjusteda 
CA19-9 (U/mL) 
≤6 29.2 0.57 (0.30-0.81) 0.54 (0.36-0.64) 38.0 0.50 (0.23-0.77) 0.50 (0.29-0.57) 
>6-18 29.2 0.32 (0.16-0.54) 0.34 (0.25-0.46) 38.0 0.29 (0.12-0.53) 0.27 (0.18-0.36) 
≤18 29.2 0.40 (0.24-0.59) 0.39 (0.36–0.43) 38.0 0.36 (0.19-0.58) 0.35 (0.31-0.38) 
>18-36 29.2 0.12 (0.04-0.28) 0.14 (0.07-0.21) 38.0 0.07 (0.02-0.24) 0.10 (0.05-0.16) 
>36-60 29.2 0.07 (0.02-0.18) 0.07 (0.03-0.14) 38.0 0.03 (0.01-0.13) 0.04 (0.01-0.10) 
ApoA2-ATQ/AT (µg/mL) 
≤6 30.3 0.21 (0.07-0.52) 0.27 (0.07-0.43) 27.7 0.14 (0.03-0.47) 0.19 (0.07-0.35) 
>6-18 30.3 0.25 (0.11-0.47) 0.22 (0.11-0.32) 27.7 0.21 (0.08-0.46) 0.15 (0.04-0.21) 
≤18 30.3 0.24 (0.12-0.42) 0.23 (0.12-0.31) 27.7 0.19 (0.08-0.40) 0.16 (0.07-0.21) 
>18-36 30.3 0.05 (0.01-0.19) 0.09 (0.02-0.16) 27.7 0.05 (0.01-0.20) 0.05 (0.00-0.09) 
>36-60 30.3 0.07 (0.02-0.18) 0.18 (0.03-0.14) 27.7 0.04 (0.01-0.15) 0.05 (0.00-0.10) 
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Table 3. Joint sensitivity and specificity of pancreatic cancer detection by time between 
blood draw and diagnosis, for pre-defined cut-points 
Lag-time 
(months) 
Threshold 
crude 
Threshold 
crude 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
CA19-9 
(U/mL) 
ApoA2-ATQ/AT 
(µg/mL) 
≤6 37 27.7 0.57 (0.29-0.82) 0.96 (0.92-0.98) 
>6-18 37 27.7 0.39 (0.22-0.59) 0.96 (0.92-0.98) 
≤18 37 27.7 0.45 (0.30-0.61) 0.96 (0.92-0.98) 
>18-36 37 27.7 0.09 (0.03-0.22) 0.96 (0.92-0.98) 
>36-60 37 27.7 0.07 (0.02-0.16) 0.96 (0.92-0.98) 
CA19-9 
(U/mL) 
ApoA2-ATQ/AT 
(µg/mL) 
≤6 38 25 0.57 (0.29-0.82) 0.98 (0.95-0.99) 
>6-18 38 25 0.36 (0.19-0.56) 0.98 (0.95-0.99) 
≤18 38 25 0.43 (0.28-0.59) 0.98 (0.95-0.99) 
>18-36 38 25 0.07 (0.01-0.19) 0.98 (0.95-0.99) 
>36-60 38 25 0.07 (0.02-0.16) 0.98 (0.95-0.99) 
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Figure 1. Box and whisker plots showing plasma levels of CA19-9 and ApoA2-ATQ/AT for 
pancreatic cancer cases and matched controls, by intervals of time from blood donation 
till diagnosis of (matched) case. 
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Figure 2. ROC curves and C-statistics for blood samples taken ≤6 months, >6-18 months,
>18-36 months and >36-60 months before cancer diagnosis. 
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